Although the biotech has only conducted preclinical studies so far, there are several potential advantages to nonviral therapies, including being quicker to develop and possibly eliminating the need for a lengthy monitoring period of patients after treatment. (fool.com)
A detailed understanding of how the NS3 protease binds to its targets might allow for the development of highly specific inhibitors with minimal effects on nonviral proteases. (sciencedaily.com)
Hybridization in situ of SV40 plaques: detection of recombinant SV40 virus carrying specific sequences of nonviral DNA (science.sciencemag.org)